National Resilience, Inc.
↗La Jolla, California, USA
Resilience is a technology-driven, full-spectrum Contract Development and Manufacturing Organization (CDMO) founded in 2020. The company focuses on advancing the development and production of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies, aiming to improve global health and secure biopharmaceutical supply chains.
Operating as a networked biomanufacturing platform, Resilience provides end-to-end solutions from early-stage development to commercial-scale manufacturing. The company maintains a significant footprint in North America with multiple facilities and has secured substantial venture and debt financing to expand its manufacturing capabilities and infrastructure.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Late Stage Venture
Total Raised:$2.46B
Investors:New Enterprise Associates, ARCH Venture Partners, 8VC, Oak Hill Advisors
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO Service Provider)
Modalities:Biologics, Cell therapy, Gene therapy, Viral vectors, Vaccines, Nucleic acids
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Taiwan Bio-Manufacturing Corporation (Biomanufacturing innovation)
COMPETITION
Position:Leader
Competitors:Lonza, Catalent, Thermo Fisher Scientific (Patheon), Samsung Biologics
LEADERSHIP
Key Executives:
Rahul Singhvi - Co-Founder and CEO
Sandy Mahatme - President, COO, and CFO
Scientific Founders:Rahul Singhvi, Drew Oetting
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of National Resilience, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with National Resilience, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.